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Abstract Global metabolic profiling currently achievable by
untargeted mass spectrometry-based metabolomic platforms
has great potential to advance our understanding of human
disease states, including potential utility in the detection of
novel and known inborn errors of metabolism (IEMs). There
are few studies of the technical reproducibility, data analysis
methods, and overall diagnostic capabilities when this tech-
nology is applied to clinical specimens for the diagnosis of
IEMs. We explored the clinical utility of a metabolomic
workflow capable of routinely generating semi-quantitative
z-score values for ~900 unique compounds, including ~500
named human analytes, in a single analysis of human plasma.
We tested the technical reproducibility of this platform and
applied it to the retrospective diagnosis of 190 individual plas-
ma samples, 120 of which were collected from patients with a
confirmed IEM. Our results demonstrate high intra-assay pre-
cision and linear detection for the majority compounds tested.
Individual metabolomic profiles provided excellent sensitivity
and specificity for the detection of a wide range of metabolic
disorders and identified novel biomarkers for some diseases.
With this platform, it is possible to use one test to screen for
dozens of IEMs that might otherwise require orderingmultiple
unique biochemical tests. However, this test may yield false
negative results for certain disorders that would be detected by
a more well-established quantitative test and in its current state
should be considered a supplementary test. Our findings de-
scribe a novel approach to metabolomic analysis of clinical
specimens and demonstrate the clinical utility of this technol-
ogy for prospective screening of IEMs.
Introduction
Inborn errors of metabolism (IEMs) are inherited disorders
typically caused by recessive mutations in genes encoding
metabolic enzymes or transmembrane transporters. The list
of recognized IEMs numbers in the hundreds and spans a wide
clinical spectrum. Multiple specimen types and analytic ap-
proaches are currently required to screen for the compendium
of IEMs (Burton 1998; Scriver 2001; Lanpher et al 2006).
IEMs have been the focus of clinical investigation for over a
century, with many now routinely screened for at birth
(Seymour et al 1997; Schulze et al 2003; Scriver 2008). Yet,
novel IEMs continue to be discovered, assisted in recent
years by whole exome sequencing (Yu et al 2013;
Thevenon et al 2014).
The study of metabolomics can involve the identification
of small molecules in biological fluids with the aim of provid-
ing a complete view of metabolic status and uncovering met-
abolic pathway perturbations (Goodacre et al 2004; Werner
et al 2008). Many prior metabolomic analyses of IEM patient
specimens have focused on targeted mass spectrometry (MS)
based approaches capable of providing absolute quantitation
for a subset of predetermined analytes (Pitt et al 2002; Kuhara
2005; Janeckova et al 2012). Untargeted MS-based and there-
fore, non-quantitative metabolomics analysis has the potential
advantage of detecting a much wider range of metabolites and
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disorders in a single test with a possible tradeoff of false neg-
atives resulting from missed analyte identifications or in cases
where small changes in concentration may be diagnostic. As
MS analytics and associated technologies have matured,
untargeted metabolomic studies have grown more precise
and comprehensive, now allowing the identification of hun-
dreds of unique plasmametabolites in a single analysis (Evans
et al 2009; Psychogios et al 2011; Trushina et al 2013).
Untargeted metabolomics studies of IEMs have been used to
expand the range of disease-associated metabolites and to
provide additional diagnostic information when paired with
concurrent quantitative population screening (Wikoff et al
2007; Denes et al 2012).
As an initial test of the possibility that an untargeted meta-
bolomics assay might allow sensitive and specific diagnosis of
a wide range of IEMs, we analyzed 190 plasma specimens
using an untargeted metabolomic workfow based on three
separate mass spectrometry platforms run in parallel.
Importantly, we approached this study as if it were a prospec-
tive screen for novel disorders; therefore we did not pool
specimens or rely on cohort analyses to detect significant an-
alyte changes. In this report we describe our results regarding
the reproducibility of metabolomic findings and explore the




All procedures followed were in accordance with the ethical
standards of the U.S. Department of Health and Human
Services and were approved by the Baylor College of
Medicine Institutional Review Board in accordance with the
Helsinki Declaration of 1975, as revised in 2000. This study
was approved with a waiver of informed consent.
Specimens used in metabolomic testing were collected from
residual patient samples in our clinical biochemical genetics
laboratory. All blood samples were initially preserved in lithi-
um heparin at the site of collection, and plasma was isolated
and shipped to our laboratory frozen. After clinical testing was
complete, samples were stored in −20 °C for 1–9 months prior
to metabolomic testing. For IEM patient samples, specimens
were selected based on existing stocks in our laboratory with
the goal of maximizing the diversity of diagnoses in our sam-
ple set. Clinical diagnoses were previously confirmed by bio-
chemical and/or molecular genetic analyses in all cases; nearly
all patients were undergoing clinical management for their dis-
order at the time of sampling. The undiagnosed patient speci-
mens were also selected from our laboratory stocks but were
prescreened to remove individuals with any biochemical find-
ings from clinical testing that were interpreted as evidence of
an IEM or of total parenteral-nutrition (TPN) at the time of
sampling.
Metabolomic analysis Metabolomic profiling was performed
using three separate mass spectrometry platforms run in parallel
essentially as described previously (Evans et al 2009). Starting
with 100 μl of plasma, small molecules were extracted in an
80 % methanol solution containing four standards (tridecanoic
acid, 4-Cl-phenylalanine, 2-flurophenylglycine, and d6-choles-
terol) used to monitor extraction efficiency. Clarified superna-
tant was split into three aliquots and dried under N2. Additional
internal standards (Standards for negative ion mode analyses
included d7-glucose, d3-methionine, d3-leucine, d8-phenylala-
nine, d5-tryptophan, Cl-phenylalanine, Br-phenylalanine, d15-
octanoic acid, d19-decanoic acid, d27-tetradecanoic acid, and
d35-octadecanoic acid. Standards for positive ion mode analy-
ses included d7-glucose, fluorophenylglycine, d3-methionine,
d4-tyrosine, d3-leucine, d8-phenylalanine, d5-tryptophan, d5-
hippuric acid, Cl-phenylalanine, Br-phenylalanine, d5-indole
acetate, d9-progesterone, and d4-dioctylpthalate.) were added
to each of three aliquots to control the quality of the chromato-
graphic and mass spectrometric analyses. Each of the three
aliquots were analyzed via a unique mass spectrometry assay:
(1) gas chromatography coupled mass spectrometry (GC-MS)
(2) liquid chromatography coupled mass spectrometry in posi-
tive ion mode (LC-MS pos), and (3) LC-MS in negative ion
mode (LC-MS neg). For GC-MS analysis, analytes were
derivatized using bistrimethyl-silyl-trifluoroacetamide and ana-
lyzed on a Trace DSQ fast-scanning single-quadruple mass
spectrometer (Thermo-Finnigan). For LC-MS analyses one
specimen was resuspended in 50 μl of 6.5 mM ammonium
bicarbonate, pH 8, for liquid chromatography mass spectrom-
etry (LC/MS) analysis in negative ion mode the other was
resuspended in 50 μl of 0.1 % formic acid in 10 % methanol
for LC/MS analysis in positive ion mode. Both resuspension
buffers contained instrument internal isotopic standards used to
monitor performance and serve as retention index markers.
Standards for negative ion mode analyses included d7-glucose,
d3-methionine, d3-leucine, d8-phenylalanine, d5-tryptophan,
Cl-phenylalanine, Br-phenylalanine, d15-octanoic acid, d19-
decanoic acid, d27-tetradecanoic acid, and d35-octadecanoic
acid. Standards for positive ion mode analyses included d7-
glucose, fluorophenylglycine, d3-methionine, d4-tyrosine,
d3-leucine, d8-phenylalanine, d5-tryptophan, d5-hippuric ac-
id, Cl-phenylalanine, Br-phenylalanine, d5-indole acetate, d9-
progesterone, and d4-dioctylpthalate. Internal standards were
chosen based on their broad chemical structures, biological
variety and their elution spectrum on each of the arms of the
platform. Chromatographic separation was completed using
an ACQUITY UPLC (Waters) equipped with a Waters BEH
C18 column followed by analysis with an Orbitrap Elite
high resolution mass spectrometer (Thermo-Finnigan)
(Evans et al 2009). For all analytic methods, metabolites
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were identified by matching the ion chromatographic reten-
tion index, accurate mass, and mass spectral fragmentation
signatures with reference library entries created from authen-
tic standard metabolites under the identical analytical proce-
dure as the experimental samples (Dehaven et al 2010).
Targeted assays For quantitative amino acid analysis, plasma
samples were acidified, and large molecules were precipitated
using equal volumes of Seraprep (Pickering Laboratories) and
200 mM lithium citrate (pH=2.2). Filtered supernatant was
analyzed via cation exchange chromatography using either a
Biochrom 30 or Hitachi L-8900 amino acid analyzer.
Quantitative acylcarnitine analysis was completed essentially
as described previously (Vreken et al 1999). Protein was pre-
cipitated using a 50% acetonitrile solution spiked with a panel
of commercially available acylcarnitine stable isotopes
(Cambridge isotope, Cat# NSK-B and NSK-B-G).
Supernatant was clarified, dried to completion under N2, and
resuspended in 3 N HCL in n-butanol. Derivatized specimens
were analyzed using an Acquity TQ tandem MS (Waters)
without chromatographic separation. Quantitative values were
calculated through comparison to spiked isotopic reference
standards.
Data analysis and statistics Raw analyte values correspond
to integrated intensity values as calculated using the area un-
der the chromatographic peak. For data analysis, raw values
were first median scaled. Next, missing values were imputed
using the minimum detected value, and finally the data were
log-transformed. Any analytes detected in fewer than 10 % of
the samples were excluded from subsequent semiquantitative
z-score analysis and were instead classified as Brare analytes^
for which a positive identification alone may be clinically
relevant. Z-scores were calculated by comparing analyte log
transformed median scaled values to the associated mean and
standard deviation found in the undiagnosed population (n=
70) with one exception; for the analysis of significant z-score
findings (Fig. 1), the z-score was calculated using the mean
and standard deviation from the entire 190 patient dataset and
statistical analysis was completed using a two-tailed
heteroscedastic student’s t-test. Welch’s two sample t- tests
were used to compare data obtained from the different disease
diagnoses. Multiple comparisons were accounted for with the
false discovery (FDR) rate method, and each FDR was esti-
mated by q-values. Pearson correlation analysis was complet-
ed by comparing the Log2 (origscale) raw metabolomic inten-
sity data to the Log2 (molar concentrations) found in targeted
analysis. To monitor process variability for each batch, the
coefficient of variation (CV) was calculated for all spiked
standards (listed above) using median scaled values.
Overall, spiked extraction standards and instrument internal
standards detected a median process variability of ≤5 % in
all batches.
Results
Overview of analyte findings and reproducibility
of metabolomic analyses
In total, we collected 120 specimens from patients with a
confirmed IEM, as well as 70 specimens from patients tested
for IEMs but with normal results. The sample set consisted of
21 different IEMs, with most disorders represented by >2
unique individuals (Table 1). The majority of diagnosed pa-
tients in this study were under clinical management at the time
of sampling. For metabolomic analysis, small molecule
analytes ranging in size from 50 to 1500 Da were extracted
from plasma and subjected to three separate MS analyses run
in parallel as described in Methods. Resultant data were an-
notated using a library containing the chromatographic and
spectral signatures of over 2500 metabolites originating from
human metabolic processes (hereafter called endogenous
analytes). This library also contained many thousands more
xenobiotic compounds and unnamed BX^ compounds that
have unique chromatographic and spectral profiles but are
not currently associated with a known analyte.
The average total analyte identifications per sample were
886, of which 489 were known endogenous compounds.
Many of these compounds (622 of the total and 397 of the
endogenous analytes) were positively identified in≥90 %
specimens studied. These reproducibly detected analytes rep-
resent many classes of biomarkers, including amino acids,
carbohydrates, lipids, and nucleotides (Fig. 1a).
To test the intra-assay precision associated with this plat-
form, a single plasma specimen was split into six aliquots and
each was independently prepared and analyzed within the
same MS batch. Using raw signal intensity values, the coeffi-
cient of variation (CV) was calculated for all analytes identi-
fied in five ormore of the replicates (964 analytes); the median
CV was 10.47 % (IQR=5.55–22.04 %) (Table S1).
For a subset of analytes, we compared metabolomic values
to true molar concentrations. This was made possible by the
fact that all samples included in this study also had targeted
quantitative analysis for selected metabolites in our clinical
laboratory. Tests most commonly ordered were plasma amino
acids or acylcarnitines (108 and 25 patients, respectively)
(Fig S1a). A total of 34 analytes routinely quantified in these
panels were also detected by metabolomic profiling. Using a
linear regression analysis, we compared metabolomic raw in-
tensity values to molar concentrations and found a strong pos-
itive correlation between testing methodologies for nearly all
compounds across a wide range of detection (median r=0.9,
IQR r=0.84–0.95; Fig S1b–d), and the breadth of analyte
values reported for each testing methodology was roughly
equivalent in most cases as estimated by the slope (m) of the
regression model (median slope =0.9, IQR slope =0.67–1.19).
One major exception, carnitine, had no correlation between
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platforms, partially as a result of low outlier values in a subset
of metabolomic analyses (Fig. S1d).
Single patient metabolomic analysis can be applied
to the detection of a wide range of IEMs
We next inspected the metabolomic data for key biochemical
signatures in known IEM patients. All 21 disorders included
in this study can be diagnosed via the measurement of small
molecule perturbations in plasma, although diet and clinical
management can sometimes suppress biochemical findings
(Table 1). To help focus our analysis to clinically relevant
perturbations, we restricted our initial inspection of patient
metabolomic profiles to endogenous analytes that met a z-
score cutoff of >2 or<−2. Although total analyte identifica-
tions were not significantly different between patients with or
without a diagnosed IEM (Fig. 1b), these two groups did have
significant differences in the number of analytes achieving the
z-score cutoff (median number for IEM patients=30.9 and
undiagnosed patients=18.7; p-value=2.9×10−5; Fig. 1c).
Using this scoring metric, 20 of the 21 disorders had mul-
tiple analyte perturbations within the pathway affected by the
respective enzyme deficiency (Table 1). We were unable to
screen for gaunidinoacetate methyltransferase (GAMT;
OMIM 612736) deficiency due to a failure to detect
guanidinoacetate, the diagnostic biomarker found elevated in
the plasma of patients with this disorder. The number of sig-
nificantly altered analytes related to the diagnosis ranged from
two metabolites in patients with trimethyllysine hydroxylase
epsilon (TMLHE; OMIM 300872) deficiency, i.e., decreased
deoxycarnitine (γ-butyrobetaine) and increased N6-
trimethyllysine (Fig. S2), to as many as 20 significant analyte
Fig. 1 Overview of metabolomic results. a The total number of analytes
identified for each class of biochemicals is shown. Overlapping black
bars indicate the number of analytes identified in 90 % or more of the
190 patient samples tested. The number of unique endogenous analytes
were calculated for IEM and undiagnosed patient populations: bBoxplots
indicate total analyte identifications; c total number of analytes with a z-
score >2 or < −2. Metabolomic data for patient #1051 with
methylmalonyl mutase deficiency (MMA) are shown in d and e. d All
endogenous analyte z-scores were plotted in ranked order; only a subset
of significant analytes are named in the plot. e Analyte z-score findings
for patient #1051 were overlaid onto the branch chain amino acid
(BCAA) degradation pathway affected in MMA patients. Each node
represents a single metabolic step. Filled numbered circles show z-
scores for significant analyte findings and the size of the circle is propor-
tionate to the z-score with red dots representing positive z-scores and blue
dots negative z-scores. Black dots represent analytes with a z-score that
was not significant; open circles indicate analytes not identified by this
analysis. The pathway position of the enzymatic deficiency,
methylmalonyl mutase, is indicated by a black star. Multiple findings
are indicated for some nodes due to the production of conjugated metab-
olites (e.g., excess propionyl-CoA is converted to propionylcarnitine and
propionylglycine). Full BCAA pathway annotation and a more compre-
hensive example of patient findings related to this pathway can be found
in Fig. S5
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perturbations that could be mapped directly up/downstream of
the enzymatic defect in patients with methylmalonic acidemia
(MMA; OMIM 25100; Figs. 1d and e; 2).
As a means of highlighting key findings and exploring the
false positive rate associated with this test, we plotted patient
values for one or two of the classic biomarkers for each
Fig. 2 Comprehensive pathway analysis provides useful diagnostic
information for branched chain amino acid metabolism. Bar charts are
shown for a representative subset of metabolites in the branched chain
amino acid pathway. Values are given as z-scores (y-axis) and dashed
gray lines indicate clinically relevant z-score cutoffs (>2 or<−2). Each
bar represents a unique patient specimen, and each color represents the
patient’s diagnosis (blue = methylmalonic aciduria, yellow = cobalamin
biosynthesis disorders, red = propionyl CoA carboxylase deficiency,
purple = HMG CoA lyase deficiency, orange = 3-methylcrotonyl CoA
carboxylase deficiency, black = isovaleryl CoA dehydrogenase deficien-
cy, and green = branched-chain ketoacid dehydrogenase deficiency). For
each disorder, a colored diamond pinpoints the pathway position of the
deficient enzyme. Numbered circles indicate intermediate analytes, 1 3-
methyl-2-oxobutyrate, 2 isobutryl-CoA, 3 methylacrylyl-CoA, 4 3-OH-
isobutryl-CoA, 5 methylmalonic semialdehyde, 6 3-methyl-2-
oxovalerate, 7 2-methylbutyryl-CoA, 8 tiglyl-CoA, 9 2-methyl-3-OH-
butyryl-CoA, 10 2-methylacetoacetyl-CoA, 11 4-methyl-2-
oxopentanoate, 12 isovaleryl-CoA, 13 3-methylcrotonyl CoA, 14 3-
methylglutaconyl CoA, 15 3-OH-3-methylglutaryl-CoA, 16 propionyl-
CoA, 17 acetyl-CoA, 18 methylcitrate, and 19 methylmalonyl-CoA. As
with standard clinical testing, many CoA conjugated pathway intermedi-
ates listed here are assayed through the measurement of carnitine or gly-
cine conjugated forms
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disorder and compared them to the findings in the undiag-
nosed patient population (n=70) (Fig. 3). Specific examples
include significant elevations of (1) hexanoylglycine in 2 of 2
patients with medium chain acyl-CoA dehydrogenase
(MCAD; OMIM 201450) deficiency, (2) alloisoleucine in 7
of 7 patients with maple syrup urine disease (MSUD; OMIM
248600), (3) methylmalonylcarnitine in 7 of 7 patients with
MMA, and (4) glutarate in 4 of 4 patients with glutaric
aciduria type 1 (GA1; OMIM 231670). In general, there were
few analyte outliers in the undiagnosed population (z-score>
2), and most analytes showed clear segregation between af-
fected and unaffected patient populations. For two different
IEMs, pathognomonic findings were provided through the
identifications of rare analytes. Thymidine was only detected
in the two patients with thymidine phosphorylase deficiency,
and argininosuccinic acid was found exclusively in the two
patients with argininosuccinic acid lyase deficiency (Fig. 3).
Presumptive treatment-related findings were also noted for
many patients. Examples include but were not limited to (i)
phenylbutyrate and/or sodium benzoate associated analyte el-
evations in patients with urea cycle disorders, (ii)
trimethylamine N-oxide elevations in patients receiving sup-
plemental carnitine (likely due to gut microbial degradation of
carnitine) (Koeth et al 2013), (iii) medium chain fatty acid
elevations in patients with long chain-related fatty acid oxida-
tion disorders likely supplemented with medium-chain tri-
glyceride (MCT) oil, (iv) creatine elevations in patients pre-
sumably receiving treatment with creatine for GAMT defi-
ciency, and (v) numerous pharmaceutical-related metabolites
(Fig. S3 and Table S1).
Fig. 3 Representative examples
of clinically relevant findings for
each inborn error of metabolism
evaluated in this study. Each dot
represents a unique patient
(normal = hollow blue circles and
IEM patient = filled red circles).
BRare analyte^ refers to analytes
only detected in the indicated
patients. See Supplemental
Tables 1 and 2 for a full listing of
clinically relevant findings for
each disorder. See Table 1 for the
full name for each disorder
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Additional applications of metabolomic data to uncover
phenotypic heterogeneity and identify novel biomarkers
We were next interested in whether the additional analyte
information provided by metabolomic analysis might help to
better predict phenotypic heterogeneity between patients with
the same disorder. Within our sample set were four
argininemia (OMIM 207800) patients, all were female and
between the ages of 16 to 24 years of age. Argininemia is
caused by autosomal recessive mutations affecting the urea
cycle enzyme arginase 1, and this disorder is diagnosed via
the measurement of plasma arginine levels (Prasad et al 1997).
Quantitative plasma amino acid analysis was completed as
part of routine clinical management for these patients and all
had comparable elevations of arginine in the absence of other
significant findings (Table S2). Metabolomic analysis of the
same specimen showed similar elevations of arginine in all
four patients, but when compared to patients #2–4, patient
#1 had much more striking perturbations of more distal com-
pounds such as urea, orotate, and homoarginine (Fig. 4). The
more severe biochemical phenotype in this patient was con-
sistent with the clinical findings; in the 3 months prior to
sampling patient #1 had been admitted to the hospital on three
separate occasions for hyperammonemic events and was re-
ceiving sodium benzoate treatment at the time of sampling
whereas patients #2–4 had more modest perturbations in distal
compounds, had not been admitted to the hospital in the
3 months prior to sampling, and were not on sodium benzoate
treatment.
To identify novel biomarkers, data from multiple different
patients were pooled and then compared to the undiagnosed
population using both a Welch’s two sample t test, as well as a
false discovery rate calculation to account for multiple sam-
pling. As an example of novel biomarker findings from this
approach, phenylketonuria (PKU; OMIM 261600) patients
(n=8) had 15 different disease-related metabolomic findings
that met our z-score cutoff, including the classic analyte ele-
vations associated with this disorder (e.g., phenylalanine and
phenylpyruvate), as well as novel biomarkers not previously
descr ibed in the plasma of PKU pat ien ts (e .g . ,
phenylalanylphenylalanine and phenylalanylleucine) (see
Table S3 for similar analyses for multiple other disorders).
Discussion
In the preceding work we describe an untargeted metabolomic
approach capable of screening for a wide variety of IEMs.
Overall, we successfully screened for 20 of 21 IEMs on the
basis of both the magnitude of key analyte perturbations, as
well as the overall pattern of findings within known metabolic
pathways. Given the breadth of analytes identified, it is likely
manymore IEMs could be detected with this platform. Results
reported herein show consistent detection of key biomarkers
across many specimens with clear segregation of disease re-
lated analyte levels between unaffected vs. affected individ-
uals in nearly all cases tested. The data analysis approach we
Fig. 4 Arginase deficiency reveals significant perturbations in distal
pathways. The green diamond indicates the location of arginase, the
deficient enzyme in these patients. Values are given as z-scores (y-axis)
and dashed gray lines indicate clinically relevant z-score cutoffs (>2 or<−2).
Patients 1–4 correspond to patient #1006–1009, respectively, in Supplemen-
tal Table 1. Pathway intermediates are indicated by numbered circles, 1
arginine, 2 argininosuccinate, 3 citrul line, 4 ornithine, 5
carbamoylphosphate, 6 orotate, 7 uridine, 8 uracil, 9 dihydrouracil, 10 3-
ureidopropionate, 11 homoarginine, 12 homoargininosuccinate, and 13
homocitrulline
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used can be applied to individual specimens without prior
establishment of disease-specific reference populations.
Therefore, in theory this platform could be used as an initial
screen for a wide range of IEMs, as long as there was prior
knowledge of the metabolic pathway and the disorder caused
significant analyte perturbations.
The key to our data analysis approach was the use of z-
scores. Using this metric, we captured the population and
technical variation for each analyte and were able to employ
biochemical pathway information to uncover diagnostic pat-
terns of analyte perturbations. The cutoff we set (z-score≥ |2|)
does not guarantee statistical significance and instead was
chosen to preserve important disease related findings while
allowing for significant reduction of data complexity (for the
average undiagnosed individual, ~19 analytes met this cutoff
(Fig. 1c)). Using a Bonferroni correction to control the family-
wise error rate (where α=0.05 and n=500) sets the signifi-
cance threshold at p<0.0001; this is equivalent to a z-
score≥ |4|. Therefore a z-score≥ |4| by itself should be strong
evidence of a clinically relevant perturbation; nearly all affect-
ed patients in our study had one or more disease related ana-
lyte that met this more stringent cutoff criterion (Table S1).
Additional information can be gained from looking at patterns
of more moderate perturbations within a pathway. For in-
stance, moderate decreases, as opposed to striking increases,
of methylmalonylcarnitine could be used to distinguish
propionic acidemia patients frommethylmalonic acidemia pa-
tients. As we study additional undiagnosed/untreated patients,
more sophisticated ratios or pattern recognition approaches
may be developed to automate analysis or allow for more
sensitive detection of disorders. Future clinical applications
of this technology should pair expert analysis with thorough
clinical notes, and diagnostic metabolomic findings should be
confirmed with second-tier testing.
Limitations of this platform were also uncovered. A num-
ber of clinically relevant plasma compounds were not identi-
fied in this study, most notably homocysteine, methylmalonic
acid, tetradecenoylcarnitine (C14:1), and guanidinoacetate
(GAA). The latter missed identification led to the failure to
detect GAMT deficiency; however, the inability to detect ho-
mocysteine, tetradecenoylcarnitine, and methylmalonic acid
was mitigated by the identification of multiple other disease
related analyte perturbations in the case of homocystinuria or
methylmalonic acidemia. Given the sample preparation
methods, it is understandable that we did not detect homocys-
teine because analysis requires a reducing reagent to release
conjugated homocysteine (Frick et al 2003). Overall,
metabolomic analysis provided excellent coverage of the ami-
no acids and acylcarnitines covered by targeted clinical tests
(Tables S4 and S5); however, long chain hydroxylated
acylcarnitines were missed and therefore this platform would
likely not be able to diagnose trifunctional protein deficiency
(OMIM 609015). For many OTC deficiency patients, only
treatment-associated findings were uncovered, similar to the
reports for clinical amino acid testing of the same specimens.
Thus, as with targeted assays, metabolomic results have to be
interpreted with the caveat that a patient’s diet and physiolog-
ical condition may mask the underlying genetic disorder. It is
worth reiterating that almost all specimens in our study were
collected while the patient was on clinical management de-
signed to alleviate their biochemical phenotype. For instance,
citrulline and/or arginine levels would likely be significantly
reduced in OTC patients if they were not receiving supple-
mentation of these amino acids. In many cases, but especially
in the OTC cohort, our dataset likely does not fully demon-
strate the capabilities of this platform in a clinical diagnostic
setting focused on undiagnosed patients.
While the results of this initial proof of concept study are
encouraging, there are additional technical considerations not
addressed in this manuscript. Further studies are needed to test
the reproducibility of this platform across multiple indepen-
dent analyses completed across a wide time frame. Additional
quantitative analyses using spiked isotopic standards would
also be beneficial to explore the reference ranges of analytes
not tested in our correlative analysis of amino acids and
acylcarnitines; this analysis would be especially important
for the subset of clinically relevant analytes found to have
poor intra-assay precision.
For the 70 undiagnosed patients in this study, metabolomic
analysis failed to uncover a new biochemical diagnosis that
could explain a patient’s phenotype. However, metabolomic
findings for two patients, #1155 and #1176, were highly suspi-
cious for biochemical disorders that were likely unrelated to
clinical findings, TMLHE deficiency and sarcosinemia
(OMIM 268900), respectively (Fig. S4). In two other cases,
t he me tabo lomic r e su l t s uncove red o rn i t h ine
transcarbamylase deficiency (OMIM 311250) female hetero-
zygotes that were misassigned to the undiagnosed population
(patients #1136 and #1166), based upon normal clinical plas-
ma amino acid results. Suspicion of an OTC diagnosis was
raised by elevations (z-score >2) of the pyrimidine pathway
intermediates uracil, uridine, orotate, and 3-ureidopropionate,
a s we l l a s g l u t am ine , i n pa t i e n t #1136 and
phenylacetylglutamine and phenylacetate elevations in patient
#1166 caused by phenylbutyrate treatment. Diagnosis in the-
se cases was confirmed through examination of the clinical
record and consultation with the attending physician.
The primary advantage of untargeted metabolomic analysis
over traditional targeted assays relates to the scope of detec-
tions possible. A single metabolomic analysis can provide
information that currently would require multiple different
clinical tests, including targeted panel assays for amino acids,
acylcarnitines, organic acids, purines, pyrimidines,
acylglycines, bile acids, and carnitine biosynthesis intermedi-
ates. In addition, we estimate that >400 endogenous analytes
identified in this study could not be detected in our clinical
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biochemical genetics laboratory even when using the full rep-
ertoire of tests available to us, including urine analyses.
Therefore, plasma metabolomic analysis may be an attractive
alternative when the patient’s phenotype is undifferentiated
(e.g., seizures, intellectual disability, or recurrent vomiting)
and the clinician is considering ordering a combination of
biochemical genetics tests, especially those for plasma amino
acids, plasma acylcarnitines, and urine organic acids. One
option would be to start with metabolomic testing and selected
other tests such as homocysteine, followed by phenotype spe-
cific testing for disorders that might be missed by
metabolomic analysis. Through this approach metabolomic
analysis may expedite diagnosis while allowing for the possi-
bility to identify novel biomarkers, IEMs, and/or sources of
phenotypic heterogeneity within a particular disease.
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